用于治疗酒精使用障碍的GLP-1受体激动剂
Gavin N Petrie1,2,3, Leah M Mayo1,2,3
1Department of Psychiatry.
The Journal of clinical investigation
|May 1, 2025
概括
与DPP-4抑制剂不同,类似葡萄糖-1受体激动剂 (GLP-1RAs) 降低了人类的酒精消耗. 这表明GLP-1RAs可能为酒精使用障碍治疗提供了一种新方法.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
背景情况:
- 类似葡萄糖-1受体激动剂 (GLP-1RAs) 是已确立的2型糖尿病 (T2D) 和肥胖症的治疗方法.
- 除了代谢调节之外,GLP-1RAs可能会影响非代谢途径.
- 双基化酶-4抑制剂 (DPP-4Is) 是另一类T2D药物.
研究的目的:
- 研究GLP-1RAs和DPP-4Is对酒精消费的影响.
- 探索GLP-1RAs在酒精使用障碍 (AUD) 中的潜在治疗应用.
主要方法:
- 人类临床评估GLP-1RA和DPP-4I对酒精摄入的影响.
- 临床前动物模型评估DPP-4抑制对酒精消费的影响.
主要成果:
- GLP-1RA与人类的酒精消耗减少有关.
- DPP-4Is对人类的酒精消费没有显著影响.
- 在临床前的动物模型中,DPP-4抑制对酒精摄入没有影响.
结论:
- GLP-1RAs在减少酒精消费方面发挥了潜在的作用.
- 这些发现表明GLP-1RAs可能是治疗酒精使用障碍的新药疗法.
- 对GLP-1RA对酒精摄入量的作用机制的进一步研究是有必要的.
更多相关视频
05:11Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder
Published on: June 23, 2023
786
07:50A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training
Published on: January 29, 2017
9.5K
相关概念视频
Glucagon-like Receptor Agonists
250
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
250
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
106
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
106
Dipeptidyl Peptidase 4 Inhibitors
117
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
117
Oral Hypoglycemic Agents: Glinides
109
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
109
CNS Depressants: Alcohol and Nicotine
151
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
151
Enzyme Inhibition
77.4K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
77.4K
